Should phosphate management be limited to the KDIGO/ KDOQI guidelines?
- 19 April 2018
- journal article
- research article
- Published by Wiley in Seminars in Dialysis
- Vol. 31 (4) , 377-381
Abstract
Hyperphosphatemia is a common complication of CKD. Prior to development of overt hyperphosphatemia, there are several adaptive mechanisms that occur to maintain normal phosphorus equilibrium in patients with CKD. These include an early and progressive rise in fibroblast growth factor 23 (FGF 23), followed by an increase in parathyroid hormone (PTH) with a decrease in 1,25‐dihydroxyvitamin D (1,25 Vit D). Over the last 20 years, a large number of studies have shown that hyperphosphatemia is a strong predictor of adverse clinical outcomes including increased incidence of vascular calcification, cardiovascular disease, and all‐cause mortality in both individuals with CKD as well as those with normal kidney function. In addition, elevations of both FGF 23 and PTH are independently associated with increased morbidity and mortality. Therefore, phosphorus lowering therapies are a vital part of the treatment strategy for patients with CKD and include dietary phosphorus restriction, treatment with phosphate binders and removal with dialysis. However, there has been a lack of high quality evidence demonstrating beneficial effects of phosphate lowering therapy on clinical outcomes. Furthermore, we do not have definitive data as to whether effective phosphate control with phosphate binders will prevent elevations in FGF 23, and whether lowering FGF 23 levels will lead to improved patient outcomes. As a result of the presently available data (or lack thereof) clinical guidelines recommend treatment only after hyperphosphatemia develops and in dialysis patients; KDOQI recommends a treatment target of less than 5.5 mg/dL, whereas KDIGO recommends treating “towards normal.” We are left with a clinical dilemma, being whether these recommendations are adequate, or should we be more aggressive in phosphate management. In this article, our goal is to discuss some of the studies concerning the adverse consequences of phosphate excess and as well as elevated FGF 23 levels, and present our opinion on what we believe the goal of treatment should be.Keywords
This publication has 50 references indexed in Scilit:
- Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysisBone, 2012
- FGF23 induces left ventricular hypertrophyJournal of Clinical Investigation, 2011
- Pharmacology, efficacy and safety of oral phosphate bindersNature Reviews Nephrology, 2011
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney diseaseKidney International, 2011
- Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patientsNephrology Dialysis Transplantation, 2010
- Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly populationAtherosclerosis, 2009
- Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney DiseaseCirculation, 2009
- Endocrine functions of bone in mineral metabolism regulationJournal of Clinical Investigation, 2008
- Disorders Involving Calcium, Phosphorus, and MagnesiumPrimary Care: Clinics in Office Practice, 2008